nk-cells

Documents about nk-cells

• Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma#918276ClinicalTrials.gov
• CD73 promotes the maturation of murine NK cells and their survival in the tumor microenvironment#336260Repositorio USS
• Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer#398326ClinicalTrials.gov
• Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma#892379ClinicalTrials.gov
• Naltrexone and Propranolol Combined With Immunotherapy#892860ClinicalTrials.gov
• To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL#852394ClinicalTrials.gov
• Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection#905226ClinicalTrials.gov
• Mathematical modelling of the efficacy and toxicity of cancer chemotherapy#938811SU+ Digital Repository
• Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor#287529ClinicalTrials.gov
• Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma#429758ClinicalTrials.gov
• NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS#448264ClinicalTrials.gov
• Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia#882443ClinicalTrials.gov
• Efficacité thérapeutique d’un anticorps humain anti-cathepsine D optimisé dans sa partie Fc en mono- et combothérapie dans les cancers du sein triple-négatifs#155998HAL (France)
• Synergistic immune interactions between T cells and natural killer cells in allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: current status and future directions#4679Europe PMC
• Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC#127600ClinicalTrials.gov
• Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer#314349ClinicalTrials.gov
• Multiplex engineering of rhesus macaque NK cells enhances homing to sites of HIV replication in B cell follicles.#356377bioRxiv / medRxiv
• Integrative Bioinformatics Analysis and Machine Learning Reveal TSPAN7 Regulates the Involution of Infantile Hemangioma via NK Cells.#382431NCBI PubMed Central
• LFA-1 Interaction with GBP-130 on Plasmodium falciparum-infected Red Blood Cells mediates NK Cell Activation and Parasite Control#150388bioRxiv / medRxiv
• Reinvigorating COTL1(high) NK cells via GITR signalling overcomes immune checkpoint blockade resistance in tsMHC-I-impaired tumours.#193432NCBI PubMed Central
• A Clinical Study of CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases#880917ClinicalTrials.gov
• Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma#993133ClinicalTrials.gov
• Targeting the TIGIT/CD155-induced metabolic checkpoint in NK cells restores anti-tumor immunity and suppresses hepatocellular carcinoma growth.#199147NCBI PubMed Central
• CLL-1 CAR-NK Cells for Relapsed/Refractory AML#966791ClinicalTrials.gov
• A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia#982472ClinicalTrials.gov
• Efectiveness of Donor IL-15-stimulated NK Cells Post Transplant Infusion in in Acute Leukemia#1007171ClinicalTrials.gov
• FT576 in Subjects With Multiple Myeloma#902434ClinicalTrials.gov
• Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in <i>Egfr</i> ‐mutated lung cancer#348396OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma#899860ClinicalTrials.gov
• Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM)#162473ClinicalTrials.gov
• Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL#217015ClinicalTrials.gov
• Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2#353264ClinicalTrials.gov
• Prospective Monocentric Study Evaluating the Circulating NK Cells Phenotype and the ImmunoScore® in Patients With Non Metastatic Rectal Cancer#390921ClinicalTrials.gov
• A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)#837590ClinicalTrials.gov
• Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer#853738ClinicalTrials.gov
• ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia#856583ClinicalTrials.gov
• Peripheral blood DNA methylation partially reports on immune cell type composition in the frontal brain#669684Europe PMC
• Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)#810949ClinicalTrials.gov
• Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)#980809ClinicalTrials.gov
• Cxcr3 promotes protection from colorectal cancer liver metastasis by driving NK cell infiltration and plasticity#159334HAL (France)
• Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma#906249ClinicalTrials.gov
• Immune synapse molecules knockout in induced pluripotent stem cells enables broad NK cell resistance in T cell progeny#308577Kyoto University Research Information Repository
• Immune synapse molecules knockout in induced pluripotent stem cells enables broad NK cell resistance in T cell progeny#308582Kyoto University Research Information Repository
• A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma#845159ClinicalTrials.gov
• An Immune Model Incorporating NK Cells and IL-12 to Predict the Efficacy of the Initial Treatment Cycle of Efgartigimod in Generalized Myasthenia Gravis.#224826NCBI PubMed Central
• Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence#283052ClinicalTrials.gov
• Clinical, immunologic, and genetic characteristics of 148 patients with natural killer cell deficiency#450375Repositorio Universidad del Desarrollo
• Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells#217033ClinicalTrials.gov
• NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma#349970ClinicalTrials.gov
• Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)#463723ClinicalTrials.gov